Overview

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899. Secondary Objectives: - To assess the change in resting, basal and total daily energy expenditure. - To assess the change in respiratory quotient, fat, protein and carbohydrate oxidation. - To assess the change in body composition and core temperature. - To assess the pharmacodynamic effects on fasting plasma glucose, biomarkers of lipid metabolism and glycated hemoglobin (HbA1c). - To assess the pharmacokinetic parameters for SAR425899 after repeated SC doses. - To assess the safety and tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi